Description: Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology. Its mission is to realize the potential of cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key cell engineering technologies, including what it believes are the most widely used methods for therapeutic gene editing currently in clinical development. Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications.
Home Page: www.brooklynitx.com
ERNA Technical Analysis
10355 Science Center Drive
San Diego,
CA
92121
United States
Phone:
212 582 1199
Officers
| Name | Title |
|---|---|
| Dr. Roger Sidhu M.D. | Chief Medical Officer |
| Dr. Matthew Angel Ph.D. | CEO & Director |
| Mr. Andrew C. Jackson | Chief Financial Officer |
| Dr. Monil Shah M.B.A., Pharm.D. | Chief Operating Officer |
| Ms. Sandra M. Gurrola | Principal Accounting Officer & VP of Fin. |
| Ms. Lynn Sadowski Mason M.S. | Exec. VP of Clinical Operations |
| Ms. Susan McClatchey | VP & Head of Quality |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4495 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 1992-10-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |